Literature DB >> 10885823

Combination therapy as a tool to prevent emergence of bacterial resistance.

J W Mouton1.   

Abstract

Emergence of resistance is an ever increasing problem. One of the methods by which emergence of resistance may possibly be prevented, or at least delayed, is the use of combination therapy. Since the emergence of resistant mutants is a direct result of selective pressure by antimicrobial therapy, the chance of mutants resistant to two antimicrobials in the parent population being present is a product of mutation frequencies, provided that resistance mechanisms are independent. Comparative studies in in vitro pharmacokinetic models and in vivo indicate that emergence of resistance is less common when combination therapy is used. This is particularly true for microorganisms known to develop resistance relatively quickly, such as Pseudomonas aeruginosa, and resistance mechanisms which occur at a relatively high frequency.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10885823     DOI: 10.1007/BF02561666

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  19 in total

1.  Can HIV infection be cured?

Authors:  J M Lange; D D Richman
Journal:  Antivir Ther       Date:  1996-08

2.  Ciprofloxacin, azlocillin, ceftizoxime and amikacin alone and in combination against gram-negative bacilli in an infected chamber model.

Authors:  D M Bamberger; L R Peterson; D N Gerding; J A Moody; C E Fasching
Journal:  J Antimicrob Chemother       Date:  1986-07       Impact factor: 5.790

3.  Two compartment kinetic model with multiple artificial capillary units.

Authors:  J Blaser; B B Stone; S H Zinner
Journal:  J Antimicrob Chemother       Date:  1985-01       Impact factor: 5.790

Review 4.  Therapy for human immunodeficiency virus infection.

Authors:  M S Hirsch; R T D'Aquila
Journal:  N Engl J Med       Date:  1993-06-10       Impact factor: 91.245

5.  Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model.

Authors:  J W Mouton; J G den Hollander
Journal:  Antimicrob Agents Chemother       Date:  1994-05       Impact factor: 5.191

6.  Treatment of ciprofloxacin- and ceftizoxime-induced resistant gram-negative bacilli.

Authors:  C E Fasching; D N Gerding; L R Peterson
Journal:  Am J Med       Date:  1987-04-27       Impact factor: 4.965

7.  Comparative activities of piperacillin, ceftazidime, and amikacin, alone and in all possible combinations, against experimental Pseudomonas aeruginosa infections in neutropenic rats.

Authors:  D E Johnson; B Thompson; F M Calia
Journal:  Antimicrob Agents Chemother       Date:  1985-12       Impact factor: 5.191

8.  Efficacy of single-agent therapy with azlocillin, ticarcillin, and amikacin and beta-lactam/amikacin combinations for treatment of Pseudomonas aeruginosa bacteremia in granulocytopenic rats.

Authors:  D E Johnson; B Thompson
Journal:  Am J Med       Date:  1986-05-30       Impact factor: 4.965

9.  Clinical and bacteriological responses to three antibiotic regimens for acute exacerbations of cystic fibrosis: ticarcillin-tobramycin, azlocillin-tobramycin, and azlocillin-placebo.

Authors:  F J McLaughlin; W J Matthews; D J Strieder; B Sullivan; A Taneja; P Murphy; D A Goldmann
Journal:  J Infect Dis       Date:  1983-03       Impact factor: 5.226

10.  Azlocillin with and without an aminoglycoside against respiratory tract infections in children with cystic fibrosis.

Authors:  H Michalsen; T Bergan
Journal:  Scand J Infect Dis Suppl       Date:  1981
View more
  29 in total

1.  Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia.

Authors:  Eric Chamot; Emmanuelle Boffi El Amari; Peter Rohner; Christian Van Delden
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

2.  In vitro double and triple synergistic activities of Polymyxin B, imipenem, and rifampin against multidrug-resistant Acinetobacter baumannii.

Authors:  Jimmy Yoon; Carl Urban; Christian Terzian; Noriel Mariano; James J Rahal
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

3.  In vitro simulation of in vivo pharmacokinetic model with intravenous administration via flow rate modulation.

Authors:  Yuan-Cheng Chen; Wang Liang; Jia-Li Hu; Gao-Li He; Xiao-Jie Wu; Xiao-Fang Liu; Jing Zhang; Xue-Qian Hu
Journal:  J Pharmacokinet Pharmacodyn       Date:  2014-10-30       Impact factor: 2.745

4.  The antimicrobial effect of blue light: What are behind?

Authors:  Tianhong Dai
Journal:  Virulence       Date:  2017-01-04       Impact factor: 5.882

5.  Alternating antibiotic treatments constrain evolutionary paths to multidrug resistance.

Authors:  Seungsoo Kim; Tami D Lieberman; Roy Kishony
Journal:  Proc Natl Acad Sci U S A       Date:  2014-09-22       Impact factor: 11.205

6.  Effects of the antibiotic component on in-vitro bacterial killing, physico-chemical properties, aerosolization and dissolution of a ternary-combinational inhalation powder formulation of antibiotics for pan-drug resistant Gram-negative lung infections.

Authors:  Sharad Mangal; Jiayang Huang; Nivedita Shetty; Heejun Park; Yu-Wei Lin; Heidi H Yu; Dmitry Zemlyanov; Tony Velkov; Jian Li; Qi Tony Zhou
Journal:  Int J Pharm       Date:  2019-02-21       Impact factor: 5.875

Review 7.  Combination therapy for treatment of infections with gram-negative bacteria.

Authors:  Pranita D Tamma; Sara E Cosgrove; Lisa L Maragakis
Journal:  Clin Microbiol Rev       Date:  2012-07       Impact factor: 26.132

Review 8.  Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis.

Authors:  Mical Paul; Karla Soares-Weiser; Leonard Leibovici
Journal:  BMJ       Date:  2003-05-24

Review 9.  Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials.

Authors:  Mical Paul; Ishay Benuri-Silbiger; Karla Soares-Weiser; Leonard Leibovici
Journal:  BMJ       Date:  2004-03-02

10.  Composite particle formulations of colistin and meropenem with improved in-vitro bacterial killing and aerosolization for inhalation.

Authors:  Sharad Mangal; Heejun Park; Lingfei Zeng; Heidi H Yu; Yu-Wei Lin; Tony Velkov; John A Denman; Dmitry Zemlyanov; Jian Li; Qi Tony Zhou
Journal:  Int J Pharm       Date:  2018-07-03       Impact factor: 5.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.